Monocytosis and Culprit Vessel in STEMI Patients

STEMI Clinical Trial

Official title:

Significance of Monocytosis and Culprit Vessel in Patients With Acute ST Elevation Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01569646
• Other study ID #: 08-021
• Status: Completed
• Phase: N/A
• First received: June 2, 2010
• Last updated: March 30, 2012
• Start date: April 2008

Study information

• Verified date: March 2012
• Source: Northwell Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Increased white blood cell count at the onset of an acute ST elevation myocardial infarction has been shown to be associated of increased incidence of heart failure and mortality. Now monocytes which are a subset of white blood cells may have a prognostic value for patients presenting with acute ST segment elevation myocardial infarction. A monocyte count of greater than 800/mm3 following acute myocardial infarction has been shown to be associated with increased incidence of left ventricular dysfunction. The investigators study would retrospectively collect data on patients with ST elevation myocardial infarction, looking for an association between high monocyte count and the culprit vessel causing the myocardial infarction. The investigators would also investigate whether monocytosis would be a marker of poor prognosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• STEMI

Exclusion Criteria:

• Patients on antibiotics and steroids

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• STEMI

Locations

Country	Name	City	State
United States	Staten Island University Hospital	Staten Island	New York

Sponsors (1)

Lead Sponsor	Collaborator
Northwell Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Association between monocyte count and culprit vessel		1 day	No
Secondary	clinical outcomes of troponin and monocyte in stemi patients		0 - 6 months	No